Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

In order to ensure normal body function, the human body is dependent on a tight control of
its blood glucose levels. This is accomplished by a highly sophisticated network of various …

Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …

Summary Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class
of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes …

Aim GLP‐1 receptor agonists (RAs) may cause nausea, vomiting or diarrhoea. The aim of
this study was to assess the risk of adverse events (AEs) with GLP‐1 RAs and their relation …

Currently, six glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are approved for
treating type 2 diabetes. These fall into two classes based on their receptor activation: short …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-
diabetic drugs that improve glycemic control and many other atherosclerosis-related …

Abstract Glucagon-like peptide-1 receptor (GLP-1R) activation promotes insulin secretion
from pancreatic beta cells, causes weight loss, and is an important pharmacological target in …

OBJECTIVE To examine the efficacy and safety of adding the once-daily glucagon-like
peptide-1 receptor agonist (GLP-1RA) lixisenatide to established basal insulin therapy alone …